How and When to Implement Precision Oncology

MAY 25, 2017

Lincoln D. Nadauld, MD, PhD, and Derrick S. Haslem, MD

Clinical implementation of precision cancer medicine and active treatment of patients with targeted therapies continue to be challenges for health care providers.
Input from a molecular tumor board confers collective insight and experience on treatment decisions and may also provide confidence for physicians who have less experience with interpreting molecular testing results.
Given the myriad genomic alterations and targeted-therapy combinations in precision oncology, innovative basket and umbrella trial designs, together with large meta-analyses and well-designed retrospective studies, are likely to provide the most clarity about clinical outcomes.